Good Feels CEO backs measure to make medical marijuana, higher-dose products more accessible and affordable
Good Feels CEO and Founder Jason Reposa had us at, “Who wants to see higher-dose Good Feels products on the market?”
He floated the question on social media, and I was not alone among fans of his company’s distinct seltzers (the ones in the Red Stripe-like wide bottle) and beverage enhancers to read further. Not everybody wants drinks that have more than 5mg of THC per serving, but there’s certainly demand for them. Reposa continued …
“I know I do! Ever since I spoke to an oncologist regarding using our products on her patients, I’ve always wanted to make stronger products for the medical market.”
And now that chance may be closer than ever. As we noted earlier this week, the state legislature’s Joint Committee on Cannabis Policy called a hearing for June 6 to field testimony on proposed cannabis bills regarding “Medical, Research, and Labs legislation.” One of the measures, An act relative to vertical integration of medical marijuana businesses, could enable smaller manufacturers to make higher-dose products via the medical market, according to Reposa.
With the Good Feels CEO set to testify on Beacon Hill this coming Tuesday, we asked to publish his prepared comments for state lawmakers ahead of time. Reposa’s letter to the joint committee is reprinted below in its entirety. -TJM Editor Chris Faraone
Dear MA House,
I hope this message finds you well. My name is Jason Reposa and I am the founder of Good Feels, a reputable and ethically-driven company within the marijuana industry. I am writing today to express my strong support for House Bill H117, which proposes the abolition of vertical integration requirements for the Massachusetts Medical Marijuana Program.
Vertical integration presents significant barriers to entry, particularly for smaller businesses and marginalized communities who are seeking to join the marijuana industry. These groups often do not have the necessary resources to own and operate every aspect of the supply chain, from cultivation and processing to distribution and retail.
While vertical integration can have its benefits in certain contexts, the mandatory nature of it within the current structure of the Massachusetts marijuana medical program limits diversity, stifles competition, and can potentially lead to inflated prices for patients in need. Moreover, it hinders the entry of specialized businesses that could drive innovation and improvements in specific segments of the industry.
By removing the vertical integration requirements, we are taking a meaningful step toward fostering an inclusive and competitive environment. It will allow for greater industry participation and, importantly, it has the potential to make medical marijuana more accessible and affordable for patients across Massachusetts.
Therefore, I respectfully urge your support for House Bill H117 in the upcoming hearing on June 6th. The passage of this bill will not only spur economic growth but also underscore our shared commitment to creating an equitable and patient-focused marijuana industry.
Thank you for your consideration and for your continued service to our great state.
Founder & CEO